panel questions and discussion (33of33) quality – oct. 16-17, 2019
Published 4 years ago • 132 plays • Length 11:14
Download video MP4
Download video MP3
Similar videos
-
16:10
panel questions and discussion (13of33) quality – oct. 16-17, 2019
-
20:05
panel questions and discussion (6of33) quality – oct. 16-17, 2019
-
20:50
panel questions and discussion (10of33) quality – oct. 16-17, 2019
-
11:28
panel questions and discussion (22of33) quality – oct. 16-17, 2019
-
9:09
panel questions and discussion (17of33) quality – oct. 16-17, 2019
-
17:47
panel questions and discussion (26of33) quality – oct. 16-17, 2019
-
18:08
panel questions and discussion (30of33) quality – oct. 16-17, 2019
-
20:49
assessment of the multi-attribute method (mam) substance (23of33) quality – oct. 16-17, 2019
-
16:24
fda research supporting emerging technologies with case studies (24of33) quality – oct. 16-17, 2019
-
25:06
quality assessment of blas, ndas, and andas (3of33) quality – oct. 16-17, 2019
-
16:06
data quality expectations for biosimilars with case studies (29of33) quality – oct. 16-17, 2019
-
22:17
pharmaceutical quality surveillance program (14of33) quality – oct. 16-17, 2019
-
26:22
application manufacturing assessment (4of33) quality – oct. 16-17, 2019
-
23:35
fda’s quality assessment and knowledge management - kasa (11of33) quality – oct. 16-17, 2019
-
30:12
panel questions and discussion (4of4) study data technical conformance webinar – jul. 13, 2017
-
17:29
panel questions and discussion (4of8) drug registration and listing using cder direct - oct 22, 2019
-
14:31
biosimilars and interchangeables - regulatory highlights (27of33) quality – oct. 16-17, 2019
-
27:33
how does fda execute pre- and post-approval inspections? (7of33) quality – oct. 16-17, 2019
-
18:17
case studies: continuous manufacturing of drug substance (21of33) quality – oct. 16-17, 2019
Clip.africa.com - Privacy-policy